Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome

Clive H Wilder-Smith, Joan Robert-Yap

Abstract

AIM: To investigate the role of endogenous pain modulatory mechanisms in the central sensitization implicated by the visceral hypersensitivity demonstrated in patients with irritable bowel syndrome (IBS). Dysfunction of modulatory mechanisms would be expected to also result in changes of somatic sensory function.

METHODS: Endogenous pain modulatory mechanisms were assessed using heterotopic stimulation and somatic and visceral sensory testing in IBS. Pain intensities (visual analogue scale, VAS 0-100) during suprathreshold rectal distension with a barostat, cold pressor stimulation of the foot and during both stimuli simultaneously (heterotopic stimulation) were recorded in 40 female patients with IBS and 20 female healthy controls.

RESULTS: Rectal hypersensitivity (defined by 95% CI of controls) was seen in 21 (53%), somatic hypersensitivity in 22 (55%) and both rectal and somatic hypersensitivity in 14 of these IBS patients. Heterotopic stimulation decreased rectal pain intensity by 6 (-11 to -1) in controls, but increased rectal pain by 2 (-3 to +6) in all IBS patients ($P < 0.05$) and by 8 (-2 to +19) in IBS patients with somatic and visceral hypersensitivity ($P < 0.02$).

CONCLUSION: A majority of IBS patients had abnormal endogenous pain modulation and somatic hypersensitivity as evidence of central sensitization.

© 2007 WJG. All rights reserved.

Key words: Diffuse noxious inhibitory controls; Endogenous pain modulation; Hypersensitivity; Irritable Bowel Syndrome; Quantitative sensory testing; Visceral pain; Sensitization
MATERIALS AND METHODS

Patients
Forty female IBS patients and 20 female healthy subjects were recruited by advertisements and through the Gastrointestinal Unit. Equal numbers of diarrhea and constipation predominant IBS patients, as defined by the Rome 2 criteria, were included and none had any evidence of organic gastrointestinal pathology after gastrointestinal workup, including endoscopy, stool and blood tests, and H₂-breath test for lactose intolerance[21]. IBS patients were required to have an average abdominal pain intensity of at least 30 on the 0-100 VAS in the two weeks before study inclusion. IBS and control subjects between 18 and 60 years of age were recruited. Controls had no gastrointestinal symptoms or evidence of chronic diseases. Main exclusion criteria in all groups were bowel resections (except appendectomy), major abdominal operations, treatment with tricyclic antidepressants, selective serotonin reuptake inhibitors, gastrointestinal prokinetics, anticholinergics, antispasmodics or analgesics in the last 14 d, serotonin reuptake inhibitors, gastrointestinal prokinetics, operations, treatment with tricyclic antidepressants, selective serotonin reuptake inhibitors, gastrointestinal prokinetics, anticholinergics, antispasmodics or analgesics in the last 14 d, and chronic pain apart from IBS-especially fibromyalgia. Institutional Ethics Committee approval was given for the study and all subjects gave their written informed consent to participation. Patients were familiarized with the study procedures on a separate day before the start of the actual testing day. The same investigator performed all tests.

Rectal distension thresholds
On the morning of the study day subjects were asked to attempt defecation and a warm water enema (300 mL) was administered to empty the rectum before rectal insertion of the lubricated, flaccid and oversized 600 mL polyethylene bag on the end of a catheter. Leakage of the rectal bag was excluded by distension with air under water before insertion and after removal at the end of the study. The bag was inflated and then pulled outwards until slight resistance was felt. The catheter was taped to the buttocks, the bag deflated and subjects positioned in a relaxed supine position. The catheter was attached to a G&J Distender® barostat (Toronto, Canada) set at an inflation rate of 27 mL/s and a safety cut-off threshold of 60 mmHg. After a resting period of 20 min the minimum distending pressure was determined and the rectal pain threshold titrated using an ascending methods of limits (AML) paradigm with 5 mmHg increments of 30 s duration followed by a decrease to baseline for 30 s until the Pain threshold (“first feeling of pain”) was reached. Subsequently, the following tests were performed in randomized sequence with a break of 30 min between tests.

Tonic rectal stimulation
Pain intensity was rated on a 100 mm anchored horizontal VAS after constant distension at the individually determined pain threshold pressure plus 20% for 120 s. This suprathereshold stimulation was chosen to induce moderate pain (visual analogue scale VAS score between 30 and 40, where 0 = no pain, 10 = unbearable pain) and was based on data from our own pilot studies.

Table 1  Characteristics of IBS patients and healthy controls. Means and 95% confidence intervals are shown

|                      | IBS n = 40 | Healthy controls n = 20 |
|----------------------|------------|-------------------------|
| Age (yr)             | 39 (36-42) | 41 (37-45)              |
| Height (cm)          | 166 (164-168) | 168 (163-173)          |
| Weight (kg)          | 69 (65-73) | 75 (67-84)              |
| Years with IBS       | 6 (3-12)   | Not applicable          |
| n with diarrhea-/constipation- predominant IBS | 20/20 | 0/0 |
| Luteal phase/non-menstruating | 19/13 | 11/9 |

Somatic stimulation: cold pressor test
Pain intensity was rated by VAS after immersion of the left foot up to the calf in a circular flow ice-water bath maintained at 4°C for 120 s. Care was taken to position the foot comfortably in the water bath, with the calf padded by cushions.

Heterotopic stimulation
The above rectal and somatic stimuli were applied concomitantly; rectal pain was rated on the VAS after 120 s. During all tests subjects were instructed to rate only their rectal pain.

Rectal compliance was calculated from the slope of the linear portion of the volume-pressure curve from each inflation sequence.

Statistical analysis
All continuous group data were calculated as means and 95% confidence intervals. Threshold values reaching cutoff were recorded as the maximum possible value. Analysis of variance (ANOVA) testing for group differences in somatic and visceral pain ratings and for changes in ratings during heterotopic stimulation was predefined, with post-hoc testing performed by Tukey’s Test in case of significance (Statistica 7.1, StatSoft Inc., Tulsa, USA). For secondary analysis IBS patients were classified as hypersensitive or non-hypersensitive based on their titrated rectal distension pressures and their somatic and rectal pain ratings using the 95% confidence intervals of healthy controls as the threshold limits for hypersensitivity, as suggested in the literature[22,23]. Correlations were assessed using multiple regression analysis with Bonferroni correction for multiple testing. A significance level of $P < 0.05$ was applied.

RESULTS
Patient characteristics are shown in Table 1. The subject groups were well matched, with no significant differences in demographics. All subjects completed the entire test series. The phase in the menstrual cycle was recorded for all subjects and there were no differences between the subject groups in the numbers of patients in the luteal phase or in those post-menopausal or post-hysterectomy.

Rectal pain thresholds and compliance
The mean pain pressure thresholds were 42 (38-46) mm
Change in rectal pain VAS vs controls) and A A A A Change in rectal pain VAS to hypersensitive IBS patients showed somatic
Pain intensity VAS ratings during somatic stimulation were significant difference).
Twenty-two of all 40 (55%) IBS patients, 14 of the 20 (80%) diarrhea-predominant IBS and 5 of the 20 (25%) constipation-predominant IBS patients were hypersensitive compared to controls (see Methods for definition). The threshold for rectal hypersensitivity was 47 mm Hg. Figure 1A illustrates the pain ratings in hypersensitive and non-hypersensitive IBS groups and in controls during tonic rectal distension. There was no difference in body weight in the hypersensitive versus non-hypersensitive groups (66 (56-76) kg and 71 (57-84) kg, respectively). Their respective rectal compliance was 4.9 (4.5-5.9) and 6.1 (4.7-7.5) (no significant difference).

**Rectal distension stimulation**

Pain intensity VAS ratings during rectal tonic suprathreshold stimulation at pain threshold +20% pressures were 39 (23-54) in controls and 42 (24-52) in IBS patients (not significant). Twenty-one (53%) of all 40 IBS patients, 16 of 20 (80%) diarrhea-predominant IBS and 5 of 20 (25%) constipation-predominant IBS patients were hypersensitive compared to controls.

**Overlap somatic and visceral hypersensitivity**

Fourteen of the 22 patients hypersensitive to the somatic stimulus were also viscerally hypersensitive. Somatic pain scores were 68 (53-83) in IBS patients hypersensitive to rectal stimulation and 32 (21-43) in IBS patients without rectal hypersensitivity (P < 0.001 versus controls and non-hypersensitive IBS) (Figure 1B). Visceral and somatic hypersensitivity correlated significantly in IBS patients (r = 0.82, P < 0.000001).

**Heterotopic stimulation**

When somatic stimulation was applied during rectal stimulation, mean group rectal pain scores decreased by 6 (-11 to -1) (mean change -16% from baseline) in healthy controls, increased by 2 (-3 to +6) (mean change +2%) in all IBS patients (P < 0.05 vs controls) and increased by 8 (-2 to +19) (mean change +12%) in IBS patients with both somatic and visceral hypersensitivity (P = 0.006 vs controls) (Figure 2). There was no significant correlation between somatic pain levels and the change in rectal pain scores during heterotopic stimulation. During heterotopic stimulation rectal pain changed by +2 (-4 to 9) in diarrhea-predominant IBS and by +1 (-6 to 7) in constipation-predominant IBS (not significant).

**DISCUSSION**

A majority of IBS patients, mainly from the IBS-D
subgroup, demonstrated either visceral or somatic hypersensitivity, with substantial but incomplete overlap of hypersensitivity to visceral and somatic stimuli. The visceral and somatic hypersensitivity states correlated significantly. While rectal hypersensitivity has previously been shown in a majority of IBS patients using various study endpoints, the few studies relating to somatic sensory dysfunction in IBS have yielded controversial results showing either somatic hypo- or hypersensitivity\[14,16-20,22,24-28\]. This discrepancy is probably best explained by the choice of different stimulation intensities, i.e suprathreshold versus threshold and painful versus non-painful, and to a lesser degree also by the selection of stimulation techniques, such as thermal versus pressure or electrical. In the current study we used painful, suprathreshold, tonic stimulation over a larger skin surface area as high-intensity and tonic stimulation have demonstrated sensitization consistently\[20-30\].

Central sensitization is a possible mechanism underlying the somatic and visceral hypersensitivity. In the current study endogenous pain modulation, one of the major mechanisms contributing to central sensitization, was shown to function as expected in healthy controls, but malfunctioned in a majority of patients with IBS. Previously, heterotopic somatic stimulation has not only been shown to reduce somatic pain intensity in healthy controls, but also discomfort or pain thresholds to gastric, duodenal and rectal distension\[3,6,9\]. Little previous data exist on endogenous pain modulation in IBS. Coffin et al\[35\] demonstrated hyperexcitability of spinal sensory modulation in IBS using a somatic nociceptive flexion reflex (R-III reflex) and concomitant rectal distension. Wilder-Smith et al\[13,37\] in two previous studies showed abnormal endogenous pain modulation and central pain processing by functional brain MRI in IBS. The current study extends this data by determining somatic as well as visceral sensory function in a larger and balanced group of IBS patients and correlating generalized sensory hypersensitivity with dysfunctional endogenous pain modulation. Hypersensitive IBS patients had evidence of endogenous pain facilitation rather than inhibition during heterotopic stimulation. Dysfunctional endogenous pain modulation is likely to reflect an imbalance between pain facilitation and inhibition with dysfunctional endogenous pain modulation in IBS, but there is no evidence for central sensitization, with visceral and somatic hypersensitivity associated with abnormal function of endogenous pain modulation and pain facilitation.

In conclusion, a majority of IBS patients demonstrated evidence for central sensitization, with visceral and somatic hypersensitivity associated with abnormal function of endogenous pain modulation and pain facilitation.

COMMENTS

Background

IBS is a very common syndrome characterized by abdominal discomfort or pain accompanied by changes in gastrointestinal motility. Peripheral and central nervous system sensitization have been proposed as an underlying mechanism in IBS. Previous brain imaging studies have demonstrated differences in the central processing of visceral nociceptive input between patients with IBS and healthy controls, mainly in the centers dealing with secondary pain processing and the assigning of affective content. Input regarding pain to the brain is subject to extensive endogenous modulation by brainstem and cortical pathways. Altered somatic as well as visceral sensory function would be expected as a consequence of central sensitization or abnormal endogenous modulation. We have previously shown abnormal endogenous modulation of visceral pain in IBS, but there is no data on modulation of somatic pain or sensory input.
**Research frontiers**

Brain imaging and new sensory testing techniques are enabling the redefining and detailed examination of brain function and pain processing in health and disease.

**Innovations and breakthroughs**

The above techniques are demonstrating abnormal processing of sensory and pain information in the brain in somatic and visceral pain disorders and are revealing an intricate functional integration of cognitive, emotional, homeostatic, motor and sensory brain centres. Understanding dysregulation in this neuroaxis, with a central role for endogenous modulation, is providing us with a new, holistic understanding of hitherto difficult to understand diseases, such as so-called ‘functional’ syndromes.

**Applications**

This and previous related publications demonstrate malfunction in one of the brain’s central regulatory mechanisms, endogenous pain modulation, in IBS. Because of the manifold connections between many major brain centres and this modulatory network, potential exist for manipulation via several avenues, including psychological, pharmaceutical as well as physical therapy. These research data can and will be applied to other related chronic pain syndromes.

**Peer review**

This is a study of 20 healthy female controls, 20 IBS-D, and 20 IBS-C women to try to further examine rectal hypersensitivity and somatic hypersensitivity using a cold pressor test of the foot. It’s an excellent work, very timely and interesting.

**REFERENCES**

1. Spiller RC. Irritable bowel syndrome. Br Med Bull 2004; 72: 15-29
2. Derbyshire SW. Visceral afferent pathways and functional brain imaging. ScientificWorldJournal 2003; 3: 1065-1080
3. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409
4. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev 2004; 27: 729-737
5. Ohara PT, Vit JP, Jasmin L. Cortical modulation of pain. Cell Mol Life Sci 2005; 62: 44-52
6. Willer JC, Roby A, Le Bars D. Psychophysical and electrophysiological approaches to the pain-relieving effects of heterotopic noceceptor stimuli. Brain 1984; 107 (Pt 4): 1095-1112
7. Talbot JD, Duncan GH, Bushnell MC, Boyer M. Diffuse noxious inhibitory controls (DNICs): psychophysical evidence in man for intersegmental suppression of noxious heat perception by cold pressor pain. Pain 1987; 30: 221-232
8. Le Bars D, Villanueva L, Bouhassira D, Willer JC. Diffuse noxious inhibitory controls (DNIC) in animals and in man. Patol Fiziol Eksp Ter 1992; 4: 55-65
9. Reineit A, Treede R, Bromb B. The pain inhibiting pain effect: an electrophysiological study in humans. Brain Res 2000; 862: 103-110
10. Bouhassira D, Danziger N, Attal N, Guiraud F. Comparison of the pain suppressive effects of clinical and experimental painful conditioning stimuli. Brain 2003; 126: 1068-1078
11. Edwards RR, Ness TJ, Weigent DA, Fillingim RB. Individual differences in diffuse noxious inhibitory controls (DNIC): association with clinical variables. Pain 2003; 106: 427-437
12. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189-196
13. Wilder-Smith CH, Schindler D, Loblad K, Redmond SM, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 2004; 53: 1595-1601
14. Chang L, Mayer EA, Johnson T, FitzGerald LD, Naliboff B. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000; 84: 297-307
15. Bouin M, Meunier P, Riberdy-Poitrats M, Poitrats P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci 2001; 46: 2542-2548
16. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001; 93: 7-14
17. Rodrigues AC, Nicholas Verne G, Schmidt S, Maederli AP. Hypersensitivity to cutaneous thermal nociceptive stimuli in irritable bowel syndrome. Pain 2005; 115: 5-11
18. Whitehead WE, Hoolkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsis HS, Schuster MM. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1999; 80: 1187-1192
19. Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727-733
20. Accarino AM, Aizpizof R, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995; 108: 636-643
21. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine Ej, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2: i83-i87
22. Metz H, Naliboff BM, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52
23. Naliboff BD, Munakata J, Fullerton S, Gracely RH, Kodner A, Harraf F, Mayer EA. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997; 41: 505-512
24. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-132
25. Bouni M, Plourde V, Boivin B, Riberdy M, Lupien F, Laganère M, Verrier P, Poitras R. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777
26. Dickhaus B, Mayer EA, Firooz N, Stains J, Conde F, Olivas T, Fass R, Chang L, Mayer M, Naliboff BD. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol 2003; 98: 135-143
27. Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Naliboff B, Vogt B, FitzGerald L, Mandelkern MA. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003; 98: 1354-1361
28. Kwan CL, Diamant NE, Mikula K, Davis KD. Characteristics of rectal perception are altered in irritable bowel syndrome. Pain 2005; 113: 160-171
29. Koltzenburg M, Torebjörk HE, Wahren LK. Nociceptor mediated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 1994; 117 (Pt 3): 579-591
30. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain 1999; 79: 75-82
31. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000; 4: 5-15
32. Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitization and pain after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and in combination. Anesth Analg 2003; 97: 526-533, table of contents
33. Magele W, Treede RD. Secondary tactile hypoesthesia: a novel type of pain-induced somatosensory plasticity in human subjects. Neurosci Lett 2004; 361: 136-139
34. Serra J, Campero M, Bostock H, Ochoa J. Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. J Neurophysiol 2004; 91: 2770-2781
35. Coffin B, Azpizof R, Malagelada JR. Somatic stimulation reduces perception of gut distention in humans. Gastroenterology 1994; 107: 1636-1642
36. Staud R, Robinson ME, Vierck CJ, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation
of second pain in normal males but not in normal females or fibromyalgia patients. *Pain* 2003; **101**: 167-174

37 **Song GH**, Venkatraman V, Ho KY, Chee MW, Yeoh KG, Wilder-Smith CH. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. *Pain* 2006; **126**: 79-90

38 **Serrao M**, Rossi P, Sandrini G, Parisi L, Amabile GA, Nappi G, Pierelli F. Effects of diffuse noxious inhibitory controls on temporal summation of the RIII reflex in humans. *Pain* 2004; **112**: 353-360

39 **Ness TJ**, Powell-Boone T, Cannon R, Lloyd LK, Fillingim RB. Psychophysical evidence of hypersensitivity in subjects with interstitial cystitis. *J Urol* 2005; **173**: 1983-1987

40 **Wilder-Smith CH**. Sensory defects in clinical subgroups of IBS patients. *Gastroenterology* 2004; **126**: A380

41 **Villanueva L**, Le Bars D. The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. *Biol Res* 1995; **28**: 113-125

42 **Drossman DA**. Gastrointestinal illness and the biopsychosocial model. *J Clin Gastroenterol* 1996; **22**: 252-254

43 **Dubner R**, Ren K. Endogenous mechanisms of sensory modulation. *Pain* 1999; Suppl 6: S45-S53

44 **Lea R**, Whorwell PJ. New insights into the psychosocial aspects of irritable bowel syndrome. *Curr Gastroenterol Rep* 2003; **5**: 343-350

45 **Mayer EA**, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. *Gastroenterology* 2006; **131**: 1925-1942

46 **Pud D**, Sprecher E, Yarnitsky D. Homotopic and heterotopic effects of endogenous analgesia in healthy volunteers. *Neurosci Lett* 2005; **380**: 209-213

47 **Lautenbacher S**, Roscher S, Strian F. Inhibitory effects do not depend on the subjective experience of pain during heterotopic noxious conditioning stimulation (HNCS): a contribution to the psychophysics of pain inhibition. *Eur J Pain* 2002; **6**: 365-374